Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 25 Feb 2020 3:05 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Epilepsy Research Program (ERP) to understand the causative links between traumatic brain injury (TBI) and epilepsy so that post-traumatic epilepsy (PTE) will be both preventable and treatable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The ERP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 ERP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. 

    Applications submitted to the FY20 ERP should address one or more of the following Focus Areas.  An application that proposes research outside of the FY20 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

    • Innovative Research:  Tools intended to better inform or improve upon how PTE research can be performed:
      • Hardware and/or software platforms that will improve seizure detection, characterization, or diagnosis
      • Bioinformatics strategies, to include machine learning, that will improve access, annotation, curation, and visualization of large and novel datasets from single or multiple sources
      • Development of new models or better characterization of existing etiologically relevant models for PTE
      • Improved characterization of the circuits involved in PTE
      • Validate targets of post-traumatic epileptogenesis or established PTE
    • Markers and Mechanisms:  Identifying markers or mechanisms via preclinical models that address PTE, which may include the following:
      • Biomarkers
      • Treatment
      • Prevention
      • Diagnosis
      • Prognosis
      • Comorbidity
    • Epidemiology:  Epidemiological characterization of PTE following TBI, which may include the following:
      • Risk factors such as demographics, genetics, anatomy, pathology, or type of injury
      • Outcomes including latency to epilepsy, comorbidities, and mortality
      • Pre-existing conditions including psychological and psychiatric risk factors
      • Treatment and healthcare outcomes research
      • Differentiation of PTE and psychogenic non-epileptic seizures (PNES)
    • Longitudinal Studies: Studies of the evolution of PTE, which may include the following:
      • Seizure frequency and semiology
      • Demographics, genetics, anatomy, pathology, or type of injury
      • Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
      • Latency between type of injury and PTE
      • Mortality
      • Treatment and healthcare outcomes research
    • Quality of Life: Studies focused on improving quality of life for individuals with PTE and their caregivers by addressing the following:
      • Psychosocial factors
      • Neuropsychological dysfunction (cognition and memory)
      • Behavioral health (anxiety, depression, post-traumatic stress disorder, impulsivity)
      • Wellness
      • Reducing stigma
      • Activities of daily living
      • Care gaps (adjunct programs, support groups, access to care)
      • Sleep disorders
      • Medication side effects

    https://cdmrp.army.mil/pubs/press/2020/20erppreann

    Idea Development Award

    Level I:  Funding Level I is intended to support early-career investigators ranging from the post-doctoral level (e.g. research associate, fellows, residents or equivalent) to within 3 years of their first independent faculty position. (mentor required)

    Level II:  The Principal Investigator (PI) must be an independent investigator at or above the level of Assistant Professor (or equivalent)

    Intent:  To support novel, innovative research to understand the magnitude and underlying mechanisms of PTE.

    • Level I is intended to support high-risk or high-gain research. Requires a mentor as part of the application.
    • Level II is intended to support a more mature, hypothesis-driven research project.

    The following Focus Areas are open to both Levels I and II:

    • Innovative Research
    • Markers and Mechanisms
    • Epidemiology
    • Longitudinal Studies

    Preliminary data, while not required, are encouraged for both levels.

    Clinical pharmacologic trials are specifically discouraged.

    Level I:

    ·      Maximum funding of $300,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Quality of Life Award

    Level I:  Funding Level I is intended to support early-career investigators ranging from the post-doctoral level (e.g. research associate, fellows, residents or equivalent) to within 3 years of their first independent faculty position. (mentor required)

    Level II:  The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To support innovative research that improves the quality of life and care for individuals living with the common symptoms of PTE and/or their families and care providers, as related to the ERP’s mission.

    • Level I is intended to support high-risk or high-gain research. Requires a mentor as part of the application.
    • Level II is intended to support PIs at or above the level of assistant professor (or equivalent) from any field or discipline.

    The following Focus Areas are open to both Levels I and II:

    • Quality of Life

    Preliminary data, while not required, are encouraged for both levels.

    Clinical pharmacologic trials are specifically discouraged.

    Level I:

    ·      Maximum funding of $300,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Research Partnership Award

    The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. 

    ·      Level I is intended to support preclinical or pre-validation research.

    ·      Level II is intended to support research requiring access to a patient cohort for a prospective study.

    Applications must include clearly stated plans for interactions between/among the partners.  The plans must include communication, coordination of research progress and results, and data sharing between all investigators and organizations participating in the project.

    The following Focus Areas are open to both Levels I and II:

    ·      Markers and Mechanisms

    ·      Epidemiology

    ·     Longitudinal Studies

    Preliminary data are required.

    Clinical pharmacologic trials are specifically discouraged

    Level I:

    ·      Maximum funding of $1,300,000 in total costs

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Level II:

    ·      Maximum funding of $3,100,000 in total costs

    ·      Maximum period of performance is 4 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 21 Feb 2020 1:03 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Multiple Sclerosis Research Program (MSRP) to support innovative and impactful research that addresses fundamental issues and gaps in Multiple Sclerosis (MS).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

     

    The MSRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity.  This pre-announcement should not be construed as an obligation by the Government.  The FY20 MSRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcements are released. 

     

    https://cdmrp.army.mil/pubs/press/2020/20msrppreann

     

    Applications submitted to the FY20 MSRP must address at least one of the Focus Areas relevant to the award mechanism as described below.

     

    Clinical Trial Award (NEW!!!)

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·        Pre-application submission is required; application submission is by invitation only.

    ·        Funds Phase I or II clinical trials relevant to MS; combinations of phases are permitted.

    ·        Funding must support a clinical trial and may not be used for preclinical studies.

    ·        Scientific rationale and preliminary data are required.

    ·         Must address at least one of the following Focus Areas:

    o    Promoting Repair, Neuroprotection, and Remyelination in MS

    Treatment of MS Symptoms

    ·       Maximum funding of $1,500,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 4 years.

     

    Exploration -Hypothesis Development Award

    Established Investigators:Independent investigators at or above the level of Assistant Professor (or equivalent) or

    New Investigators:

    ·        Independent investigators no more than  3 years from the start of their  faculty position

    ·        Must not have a Research Project Grant (R01) or similar non-mentored award

    UPDATED!!!

    ·        Pre-application submission is required; application submission is by invitation only.

    ·        Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.

    ·        Preliminary data not required.

    ·        Clinical trials not allowed.

    ·         New Investigator Option supports applicants early in their faculty appointments.

    ·         Must address at least one of the following Focus Areas:

    o    Promoting Central Nervous System Regenerative Potential in Demyelinating Conditions

    o    Correlates of Disease Activity and Progression in MS

    o    Biology and Measurement of MS Symptoms

    Identify the Role of Factors in MS Etiology, Prodome, Onset, and Evolution, Including Repair Processes (NEW!!!)

    ·       Maximum funding of $150,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 2 years.

     

    Investigator-Initiated Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·        Pre-application submission is required; application submission is by invitation only.

    ·        Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.

    ·        Preliminary data required.

    ·        Clinical trials not allowed.

    ·         Must address at least one of the following Focus Areas:

    o    Promoting Central Nervous System Regenerative Potential in Demyelinating Conditions

    o    Correlates of Disease Activity and Progression in MS

    o    Biology and Measurement of MS Symptoms

    Identify the Role of Factors in MS Etiology, Prodome, Onset, and Evolution, Including Repair Processes (NEW!!!)

    ·       Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 20 Feb 2020 2:53 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

     

    The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities.  This pre-announcement should not be construed as an obligation by the Government.  The FY20 LCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. 

     

    Applications submitted to the FY20 LCRP must address one or more of the following Areas of Emphasis:

     

    • Identify innovative strategies for the screening and early detection of lung cancer.
    • Understand the molecular mechanisms of initiation and progression to lung cancer.
    • Identify innovative strategies for prevention of the occurrence of lung cancer.
    • Identify innovative strategies for the treatment of lung cancer.
    • Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
    • Develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.
    • Understand mechanisms of resistance to treatment (primary and secondary).
    • Understand contributors to lung cancer development other than tobacco.
    • Identify innovative strategies for lung cancer care delivery (disparities/clinical management/ surveillance/symptom management).

     

    Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY20 LCRP during programmatic review.   Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

     

    • Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
    • Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
    • Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
    • Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

    https://cdmrp.army.mil/pubs/press/2020/20lcrppreann

     

    Concept Award

    Investigators at all academic levels

    ·     Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.

    ·     Emphasis on innovation.

    ·     Clinical trials not allowed.

    ·     Preliminary data discouraged.

    ·     Relevance to military health strongly encouraged.

    ·       Maximum funding of $100,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 1 year.

     

    Career Development Award

    ·     Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment

    ·     Mentor:  At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research

    ·     Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.

    ·     Clinical trials not allowed.

    ·     Preliminary data not required.

    ·     Relevance to military health strongly encouraged.

    ·       Maximum funding of $250,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 2 years.

     

    Idea Development Award

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or

    New Investigators:  Investigators that meet the following criteria by the application submission deadline date:

    ·        Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award

    ·        Are within 10 years of first faculty appointment (or equivalent)

    ·       Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.

    ·       Emphasis on innovation and impact.

    ·       New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.

     

    ·       Clinical trials not allowed.

    ·       Preliminary data required.

    ·       Relevance to military health strongly encouraged.

    ·       Maximum funding of $350,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 2 years.

     

     

    Investigator-Initiated Translational Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·       Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.

    ·       This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:

    o    Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts

    o    Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug submission

    o    Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials

    ·       Preliminary data required.

    ·       Relevance to military health strongly encouraged.

    ·       Maximum funding of $400,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 2 years.

     

    Clinical Translational Research Partnership Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·       Supports translational studies that include a clinical trial.

    ·       This mechanism is intended to fund partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications.

    o    One partner is strongly encouraged to be from either a military treatment facility or a Department of Veterans Affairs medical center.

    ·       Non-traditional partnerships are encouraged

    ·       Preliminary data required.

    ·       Relevance to military health strongly encouraged.

    ·       Patient research advocate involvement encouraged.

    ·       Biostatistician involvement encouraged.

    ·      Maximum combined funding of $1,200,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.


    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.orgprior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 4 Feb 2020 2:20 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Tick-Borne Disease Research Program (TBDRP) to support innovative, high-impact tick-borne disease research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The TBDRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 TBDRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.

    Applications submitted to the FY20 TBDRP must address one or more of the following Focus Areas:

    *            Diagnosis:

    o            Sensitive and specific direct detection diagnostic assay for Borrelia and/or other TBD pathogens.  Assay should ultimately be amenable for implementation in a typical clinical setting, cost-effective, and rapid (diagnosis in < 24 hours).

    o            Diagnostic biomarker panel for Lyme disease and other TBDs that distinguishes TBD infection from other febrile illnesses.

    o            Approaches for Lyme disease or other TBD diagnosis capable of distinguishing active infection and previous exposure, and/or monitoring response to treatment.

    o            Innovative and new approaches that provide diagnosis for a single or multiple TBD infections from a single sample.

    *            Treatment: 

    o            Therapeutic strategies for treating acute and persistent TBDs.  Novel therapeutics and/or non-antibiotic modalities for treating TBDs are encouraged.

    o            In vitro interrogation of potential treatments designed to mitigate development of long-term sequelae following infection with bacterial, parasitic, or viral tick-borne (TB) agents.

    *            Immunomodulatory approaches to treat the inflammatory response to infection.

    *            Prevention: 

    o            Drugs, antibodies, or other novel approaches that can be administered and/or utilized prophylactically to prevent human TBD infection.

    o            Safe and effective human vaccines for TBDs.

    o            Identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions.

    o            Understanding the ecology of understudied TBD vectors and reservoirs with emphasis on how it relates to human risk.

    *            Pathogenesis:

    o            Pathogenesis of persistent clinical manifestations associated with Lyme disease.

    o            Immune evasion and/or tolerance of TB pathogens (Lyme and/or other TBDs).

    o            Effects of tick sialome on human infection, immune response, disease progression, and pathogen dissemination.

    o            TB infections and co-infections (simultaneous or sequential) and their effects on human disease severity, the local and systemic immune response, and/or pathogen synergy and competition.

    o            Red meat allergy (allergic response to alpha-gal).

    https://cdmrp.army.mil/pubs/press/2020/20tbdrppreann

    Career Development Award

    Principal Investigator (PI): 

    Investigators within 10 years of completing terminal degree (excluding time in medical residency or on family medical leave) at the time of application submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded

    Mentor:  Independent investigators at or above the level of Associate Professor (or equivalent); must be an experienced tick-borne diseases researcher as demonstrated by a recent (last 5 years) history of funding and publications in tick-borne diseases research, specifically in the field (pathogen and associated methods) of the proposed studies.

    The PI and Mentor may be at different organizations.

    *            To fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.

    *            Career Development Plan is required for invited application submission.  Plan should be prepared with appropriate guidance from the Mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the PI will gain experience in tick-borne disease research.  PI's institution must demonstrate a commitment to the PI through a minimum of 75% protected research time for tick-borne disease research.  The application must include clearly stated plans for interactions and communication coordination between the PI and Mentor.

    *            Mentorship is required

    *            Preliminary data is encouraged, but not required.

    *            Clinical trials are not allowed; human studies/clinical research are permitted.

    *            Preproposal is required; application submission is by invitation only.

    *            Maximum funding of $300K for direct costs (plus indirect costs)

    *            Maximum period of performance is 3 years

    Idea Development Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    *            To fund research that could lead to impactful discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme diseases and/or other tick-borne illnesses

    *            Research should be conceptually innovative, exhibit high levels of creativity, or challenge existing research paradigms.

    *            Applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed.

    *            Preliminary data is encouraged, but not required.

    *            Clinical trials are not allowed; human studies/clinical research are permitted.

    *            Preproposal is required; application submission is by invitation only.

    *            Maximum funding of $600K for direct costs (plus indirect costs)

    *            Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org.  For more information about the TBDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).


  • 21 Jan 2020 9:22 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act providing funding to the Department of Defense ALSRP to support innovative and impactful research to develop new treatments for ALS.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

     

    FY20 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.    

    https://cdmrp.army.mil/funding/alsrp

     

    Therapeutic Development Award - Pre-Application March 27, 2020

    Independent investigators at all academic levels (or equivalent)

    ·      Pre-application is required; full application submission is by invitation only.

    ·      Supports preclinical secondary validation and IND-enabling studies of therapeutics for ALS.

    ·      Preliminary data is required, including efficacy in at least one ALS-relevant model system with a lead molecule/class of compounds.

    ·      Biomarker development and/or characterization (if not already validated), in parallel to the main therapeutic effort, is a critical component of the TDA proposal.

    ·      Maximum funding of $1,000,000 for direct costs plus indirect costs

    ·      Maximum period of performance is years

     

    Therapeutic Idea Award - Pre-Application March 27, 2020

    Independent investigators at all academic levels (or equivalent)

    ·      Pre-application is required; full application submission is by invitation only.

    ·      Supports hypothesis-driven preclinical therapeutic development.

    ·      Preliminary data are not required.

    ·      Projects focusing primarily on investigating ALS pathophysiology are outside the scope of this award mechanism.

    ·      Early Career Investigators are encouraged to apply.

    ·      Therapeutic Relevant Biomarker Option: Applications which include the development of biomarkers in parallel with the main therapeutic advancement effort, and that meet the criteria outlined in the Funding Opportunity Announcement, will qualify for a higher level of funding.

    ·      Maximum funding of $500,000 for direct costs plus indirect costs

    ·      Maximum funding of $600,000 for direct costs plus indirect costs if applying for the Therapeutic Relevant Biomarker Option

    ·      Maximum period of performance is years

     

    New for FY20! Clinical Development Award - Pre-Application March 27, 2020

    Independent investigators at all academic levels (or equivalent) 

    ·      Pre-application is required; full application submission is by invitation only.

    ·      Supports leveraging of human-based ALS resources through correlative clinical research.

    ·      Early Career Investigators and/or Early Career Physician Scientists are encouraged to apply.

    ·      Types of efforts that will be supported include:

    o  Using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis

    o  Correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes

    o  Adding a secondary aim/goal to an anticipated/ongoing clinical trial, not otherwise supported by the trial

    o  Studies to evaluate optimizing components of current ALS clinical care

    ·      Maximum funding of $300,000 for direct costs plus indirect costs

    ·      Maximum period of performance is years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.  

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 14 Jan 2020 2:59 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $15 million to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The OPORP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 OPORP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. 

    OPORP supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service members and Veterans with limb loss and/or limb impairment. The intent of this research is to generate clinically useful evidence that will enhance and optimize patient outcomes. Applications submitted to the FY20 OPORP must address at least one of the following Focus Areas:

    • Orthoses or Prostheses Form: Optimize patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
    • Orthoses or Prostheses Fit: Optimize patient outcomes related to human-device interface through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
    • Orthoses or Prostheses Function: Optimize patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

    https://cdmrp.army.mil/pubs/press/2020/20oporppreann

     

    Clinical Research Award

    Independent investigators at all academic levels (or equivalent).

    • Funding Level 1 supports pilot research that has the potential to make significant advancement toward clinical translation. Preliminary data are allowed but not required.
    • Funding Level 2 supports research that has the potential to make significant impact toward clinical translation. Preliminary data and/or published data from the literature that are relevant to the orthotic and/or prosthetic device outcomes and support the rationale for the proposed research are required.
    • ·         Preclinical studies using animals are not allowed.

    Funding Level 1

    • Maximum funding of $350,000 for total costs (direct plus indirect costs).
    • Maximum period of performance is 2 years.

    Funding Level 2

    • Maximum funding of $2 million for total costs (direct plus indirect costs).
    • ·         Maximum period of performance is 4 years.

    Clinical Trial Award

    Independent investigators at all academic levels (or equivalent).

    • Supports clinical trials with the potential to have a significant impact on improving the health and well-being of Service members, Veterans, and other individuals living with limb loss and/or limb impairment.
    • Funding Level 1 supports pilot clinical trials which are exploratory and involve limited human exposure with the potential to make significant advancement toward clinical translation. Preliminary data are allowed but not required.
    • Funding Level 2 supports clinical trials with the potential to make significant advancement toward clinical translation. Preliminary data relevant to the proposed clinical trial are required.
    • Preclinical research is not allowed.

    Funding Level 1

    • Maximum funding of $350,000 for total costs (direct plus indirect costs).
    • Maximum period of performance is years.

    Funding Level 2

    • Maximum funding of $4 million for total costs (direct plus indirect costs).
    • ·         Maximum period of performance is years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 27 Dec 2019 10:49 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $3 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on BMF diseases. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The BMFRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 BMFRP Program Announcement and General Application Instructions for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcement is released.

    https://cdmrp.army.mil/pubs/press/2020/20bmfrppreann

    Idea Development Award

    Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from first faculty appointment (or equivalent) or

    Early Career Investigators:
    Independent investigators at the level of Assistant Professor (or equivalent) and less than 10 years from first faculty appointment (or equivalent).

    • Preproposal is required; full application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF.
    • Strong BMF research team.
    • Research project should include well-formulated, testable hypothesis based on strong scientific rationale and a well- developed and articulated research approach.
    • Translational potential should be considered and described.
    • May include relevant preliminary data.
    • Clinical trials will not be supported.
    • Maximum funding of $325,000 in direct costs (plus indirect costs).
    • Period of performance not to exceed 2 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 26 Dec 2019 3:30 PM | Hawk Tran (Administrator)

    The Fiscal Year 2020 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):

    • Amyotrophic Lateral Sclerosis Research Program - $20.0 million
    • Autism Research Program - $15.0 million
    • Bone Marrow Failure Research Program - $3.0 million
    • Breast Cancer Research Program - $150.0 million
    • Chronic Pain Management Research Program - $15.0 million
    • Combat Readiness Medical Research Program - $10.0 million
    • Duchenne Muscular Dystrophy Research Program - $10.0 million
    • Epilepsy Research Program - $12.0 million
    • Gulf War Illness Research Program - $22.0 million
    • Hearing Restoration Research Program – $10.0 million
    • Kidney Cancer Research Program - $40.0 million
    • Joint Warfighter Medical Research Program - $40.0 million
    • Lung Cancer Research Program – $14.0 million
    • Lupus Research Program - $10.0 million
    • Melanoma Research Program - $20.0 million
    • Military Burn Research Program – $10.0 million
    • Multiple Sclerosis Research Program - $16.0 million
    • Neurofibromatosis Research Program - $15.0 million
    • Orthotics and Prosthetics Outcomes Research Program- $15.0 million
    • Ovarian Cancer Research Program - $35.0 million
    • Pancreatic Cancer Research Program - $6.0 million  (new for FY 20)
    • Parkinson's Research Program – $16.0 million
    • Peer Reviewed Alzheimer's Research Program – $15.0 million
    • Peer Reviewed Cancer Research Program (14 Topics) - $110 million
    • Peer Reviewed Medical Research Program (44 Topics) - $360 million
    • Peer Reviewed Orthopaedic Research Program - $30 million
    • Prostate Cancer Research Program - $110 million
    • Rare Cancers Research Program - $7.5 million  (new for FY 20)
    • Reconstructive Transplant Research Program - $12.0 million
    • Scleroderma Research Program - $5.0 million (new for FY 20)
    • Spinal Cord Injury Research Program - $40.0 million
    • Tick-Borne Disease Research Program - $7.0 million
    • Tuberous Sclerosis Complex Research Program - $6.0 million
    • Vision Research Program - $20.0 million

    https://cdmrp.army.mil/pubs/press/2020/funding_press_release20

    Pre-announcements and comprehensive Program Announcements will be forthcoming. The pre-announcements will provide a general overview of the anticipated funding mechanisms. The Program Announcements will include detailed descriptions of funding mechanisms, evaluation criteria, submission requirements, and deadlines. Each Program Announcement may be downloaded from the Grants.gov website http://www.grants.gov, or the CDMRP website https://cdmrp.army.mil upon its release.

    For email notification when pre-announcements and Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.

    For more information about the CDMRP, our research programs, previous awardees, as well as research highlights and videos, please visit the website at https://cdmrp.army.mil.

    Point of Contact:

    CDMRP Public Affairs
    301-619-7783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 26 Dec 2019 3:30 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $10 million to the Department of Defense Military Burn Research Program (MBRP) to support a research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities. Outcomes of successful research are anticipated to benefit Service members, Veterans, and the general public.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The MBRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 MBRP Program Announcement and General Application Instructions for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcement is released. 

    The MBRP encourages applications that propose research that advances the development or refinement of interventions, technologies, or knowledge projects that will enable non-medical personnel or medical first responders to provide appropriate burn care closer to the point of injury to enhance the potential for better long-term outcomes. Applications submitted to the FY20 MBRP must address at least one of the following Focus Areas:   

    • Burn care solutions for use by non-medical first responders in a Prolonged Field Care (PFC) scenario.
    • Burn care solutions for use by the medical first responder in the pre-hospital setting (not necessarily in a PFC scenario).

    https://cdmrp.army.mil/pubs/press/2020/20mbrppreann

     

    Clinical Translational Research Award

    Independent investigators at all academic levels (or equivalent) may be named as PI in the application.

    • Supports clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, pre-clinical, or clinical research findings to the care of the burn-injured patient.
    • The proposed study must include clinical research, and may include initial proof of concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
    • Large randomized clinical trials are discouraged.
    • Preliminary data is required.
    • Animal research is not allowed.
    • ·         Pre-application is required; application submission is by invitation only.
    • Maximum funding of $1.5 million (M) for total costs (direct costs plus indirect costs)
    • ·         Maximum period of performance is 4 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 26 Dec 2019 3:28 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation provides $15 million (M) to the Department of Defense Autism Research Program (ARP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    Subject to the FY20 Congressional appropriation for ARP funding, FY20 ARP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcements are released. 

    https://cdmrp.army.mil/pubs/press/2020/20arppreann

    Clinical Trial Award

    Investigators at or above the level of Assistant Professor (or equivalent), or

    Nested Early-Career Investigator Option: Investigators at or above the level of Assistant Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:

    • Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
    • Is no more than 7 years from the receipt of a terminal degree
    • ·         Has the freedom to commit at least 50% time to the project
    • Supports research with the potential to have a major impact on the treatment and/or management of ASD.
    • Preliminary data relevant to the proposed clinical trial are required.
    • Pre-application is required; application submission is by invitation only.
    • ·         Nested Early-Career Investigator Option: Supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research.
    • Maximum funding of $2,000,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.
    • ·         Nested Early-Career Investigator Option:
    • Maximum funding of $2,300,000 for direct costs (plus indirect costs).
    • ·         Maximum period of performance is 4 years.

    Clinical Translational Research Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    • Supports early-phase, proof-of-principle clinical trials with the potential to have a major impact on the treatment and/or management of ASD.
    • Preliminary data relevant to the proposed project are required.
    • ·         Pre-application is required; application submission is by invitation only.
    • Maximum funding of $600,000 for direct costs (plus indirect costs).
    • ·         Maximum period of performance is 3 years.

     

    Idea Development Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    Multiple PI Option: 
    Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator and receive a separate award. 

    • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes. Preliminary data relevant to the proposed project are required.
    • Pre-application is required; application submission is by invitation only.
    • ·         Clinical trials or applications including a clinical trial aim are not allowed.
    • Maximum funding of $550,000 for direct costs (plus indirect costs).
    • ·         Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software